Highlights Immutep Limited

Equities

IMM

AU000000IMM6

Delayed Australian S.E. Other stock markets 23:46:18 2024-05-09 EDT			5-day change	1st Jan Change
0.465 ^AUD	0.00%		+6.90%	+34.78%

05-02	Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	CI
05-02	Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	05-02	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	05-01	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	04-30	CI
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	04-25	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	04-24	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	04-24	CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	04-18	CI
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	04-17	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	04-17	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	04-16	MT
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	03-05	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	02-27	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	01-04	CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	12-21	CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government	12-07	MT
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022	12-06	MT
Immutep Limited Announces Completion of Patient Enrollment in the Tacti-003 (Keynote-Pnc-34) Phase Iib Trial	11-09	CI
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	11-09	CI
Immutep Limited Announces Completion of the Safety Lead-In and Opening of the Randomized Phase Ii of the Aipac-003 Phase II/III Trial in Metastatic Breast Cancer	11-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immutep Limited

Equities

IMM

AU000000IMM6

Highlights

Filters